Drugs / PXL065
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05200104 | Sep 2023 → Sep 2024 | adrenoleukodystrophy | Poxel SA | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04321343 | Sep 2020 → Jun 2022 | metabolic dysfunction-associated steatohepatitis | Poxel SA | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PXL065 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05200104 ↗ |
| Route | Oral | “PXL065 oral tablet” NCT04321343 ↗ |